Phase I trial of carboplatin in combination with irinotecan and paclitaxel split-dosed on days 1 and 8

Phase 1

Completed

• Conditions: Patients with advanced refractory cancers; Cancer - Other cancer types

• Registration Number: ACTRN12609000790246
• Lead Sponsor: Hellenic Cooperative Oncology Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-09-10
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Performance status: World Health Organization (WHO) 2 Life expectancy: At least 3 months Hematopoietic: Platelet count at least 100,000/mm3 Absolute neutrophil count at least 3,000/mm3 Absolute lymphocyte count at least 1,500/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL Transaminase no greater than 2.5 times upper limit of normal Renal: Creatinine no greater than 1.4 mg/d

Exclusion Criteria

Cardiovascular: myocardial infarction within 6 months. Current, uncontrolled cardiac arrhythmias. History of anaphylactic reactions. Pregnancy. Serious uncontrolled, concurrent medical disorders.

Study & Design

• Study Type: Interventional
• Study Design: Not specified